Startseite Determination of Free Apolipoprotein(a) in Serum by Immunoassay and Its Significance for Risk Assessment in Patients with Coronary Artery Disease
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Determination of Free Apolipoprotein(a) in Serum by Immunoassay and Its Significance for Risk Assessment in Patients with Coronary Artery Disease

  • Wolfgang Herrmann , Sabine Quast , Kai Wolter , Hartmut Eger , Stefan T. Kießig , Harry Hahmann , Jörg Kreuter und Ewald Molinari
Veröffentlicht/Copyright: 1. Juni 2005
Veröffentlichen auch Sie bei De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Band 37 Heft 1

Abstract

This paper describes a new enzyme-linked ligand sorbent assay (ELLSA) to quantify free apolipoprotein(a) (apo(a)). The new test immobilizes free apo(a) utilizing a specific peptide that carries the amino acid sequence of a non-covalent apo(a) binding site on apoB3375–3405 (ligand-peptide). The ligand-peptide coupled to Sepharose was used in affinity chromatography to separate free apo(a) from whole serum. Isolated free apo(a) consisted of full length apo(a) and smaller apo(a). Additionally, free apo(a) levels determined by ELLSA as well as by electroimmunodiffusion correlated moderately well. Significantly increased serum concentrations of free apo(a) were found in coronary artery disease. The mean value of free apo(a) was three times higher in patients than in controls while the lipoprotein(a) (Lpla)) concentration was doubled. Utilizing receiver operating characteristic diagrams, it was shown that the free apo(a)-ELLSA had a better diagnostic test performance in atherosclerotic risk assessment than the Lp(a)-test: specificity free apo(a)-ELLSA 0.77, Lp(a)-test 0.81 [with (a:a)-enzyme immunoassay (EIA)] to 0.83 [with (a:B)-EIA]; sensitivity free apo(a)-ELLSA 0.57, Lp(a)-test 0.36 to 0.40. In conclusion, the new free apo(a)-ELLSA allows for the specific quantification of free apo(a). This provides an interesting indicator for atherosclerotic risk assessment.

:
Published Online: 2005-06-01
Published in Print: 1999-01-01

Copyright (c)1999 by Walter de Gruyter GmbH & Co. KG

Artikel in diesem Heft

  1. Structure, Function and Clinical Significance of Transferrin Receptors
  2. Cardiac Troponin I and Troponin T: Recent Players in the Field of Myocardial Markers
  3. Determination of Free Apolipoprotein(a) in Serum by Immunoassay and Its Significance for Risk Assessment in Patients with Coronary Artery Disease
  4. Fecal Tumor Necrosis Factor alpha, Eosinophil Cationic Protein and IgE Levels in Infants with Cows Milk Allergy and Gastrointestinal Manifestations
  5. Detection of GB Virus C/Hepatitis G Virus RNA by Reverse-Transcription Polymerase Chain Reaction
  6. Development of Capillary Electrophoresis as An Alternative to High Resolution Agarose Electrophoresis for the Diagnosis of Multiple Sclerosis
  7. Urokinase and Plasminogen Activator-Inhibitor (PAI-1) Status in Primary Ovarian Carcinomas and Ovarian Metastases Compared to Benign Ovarian Tumors as A Function of Histopathological Parameters
  8. Intracellular and Extracellular, Ionized and Total Magnesium in Pre-Eclampsia and Uncomplicated Pregnancy
  9. Phospholipases A2 in Gastric Juice of Helicobacter pylori – Positive and Negative Individuals
  10. Appropriateness of Physicians Requests of Laboratory Examinations in Primary Health Care: An Over- and Under-Utilisation Study
  11. Effect of the Hemoglobin-Based Oxygen Carrier HBOC-201 on Laboratory Instrumentation: Cobas Integra, Chiron Blood Gas Analyzer 840, Sysmex™SE-9000 and BCT
  12. Current System of Undergraduate and Postgraduate Education in Clinical Chemistry in Croatia
  13. The Effects of Fasting on Blood Antioxidant Potential and Malondialdehyde Levels
  14. Biological Variation in Lipoprotein(a)
  15. Molecular Biology or Steroid and Nuclear Hormone Receptors by Leonard P. Freedman, editor
Heruntergeladen am 22.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/CCLM.1999.003/html
Button zum nach oben scrollen